Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) EBIT (2016 - 2025)

Historic EBIT for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to -$4.8 million.

  • ProPhase Labs' EBIT rose 2648.15% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.6 million, marking a year-over-year increase of 831.94%. This contributed to the annual value of -$38.6 million for FY2024, which is 8204.05% down from last year.
  • As of Q3 2025, ProPhase Labs' EBIT stood at -$4.8 million, which was up 2648.15% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, ProPhase Labs' EBIT ranged from a high of $16.1 million in Q1 2022 and a low of -$17.3 million during Q4 2024
  • In the last 5 years, ProPhase Labs' EBIT had a median value of -$3.9 million in 2025 and averaged -$2.0 million.
  • The largest annual percentage gain for ProPhase Labs' EBIT in the last 5 years was 189724.05% (2021), contrasted with its biggest fall of 255762.71% (2021).
  • Quarter analysis of 5 years shows ProPhase Labs' EBIT stood at $13.7 million in 2021, then tumbled by 137.22% to -$5.1 million in 2022, then plummeted by 115.3% to -$11.0 million in 2023, then tumbled by 57.77% to -$17.3 million in 2024, then skyrocketed by 72.45% to -$4.8 million in 2025.
  • Its EBIT stands at -$4.8 million for Q3 2025, versus -$3.9 million for Q2 2025 and -$3.7 million for Q1 2025.